The nonreceptor protein tyrosine phosphatase SHP2 (encoded by PTPN11) integrates
growth and differentiation signals from receptor tyrosine kinases (RTKs) into the …

The protein tyrosine phosphatase SHP2 encoded by PTPN11 is a promising therapeutic
target for cancer therapy, while the multifaceted roles of SHP2 complicate the drug discovery …

Purpose: SHP2 inhibitors offer an appealing and novel approach to inhibit receptor tyrosine
kinase (RTK) signaling, which is the oncogenic driver in many tumors or is frequently …

Dysregulation or aberrant signaling transduction contributes to tumorigenesis. Targeting
these abnormal signaling pathways becomes an effective anticancer strategy. However …

The protein tyrosine phosphatase SHP2 encoded by PTPN11 is a promising therapeutic
target for cancer therapy. The dynamic change of SHP2 between closed and open …

Although KRASG12C inhibitors show clinical activity in patients with KRAS G12C mutated
non–small cell lung cancer (NSCLC) and other solid tumor malignancies, response is …

Loss of the RAS GTPase-activating protein (RAS-GAP) NF1 drives aberrant activation of
RAS/MEK/ERK signaling and other effector pathways in the majority of malignant peripheral …

SHP2 is a protein tyrosine phosphatase that plays a critical role in the full activation of the
Ras-MAPK pathway upon stimulation of receptor tyrosine kinases, which are frequently …

Treatment of high-risk neuroblastoma typically incorporates multiagent chemotherapy,
surgery, radiation therapy, autologous stem cell transplantation, immunotherapy, and …

Encoded by PTPN11, the Src-homology 2 domain-containing phosphatase 2 (SHP2)
integrates signals from various membrane-bound receptors such as receptor tyrosine …